Inactive Instrument

China Biologic Products Holdings, Inc.

Equities

CBPO

KYG215151047

Biotechnology & Medical Research

China Biologic Products Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020

August 17, 2020 at 05:02 pm

China Biologic Products Holdings, Inc. announced earnings results for the second quarter ended June 30, 2020. For the second quarter, the company announced total revenue was USD 111.112 million compared to USD 135.696 million a year ago. Operating income was USD 42.691 million compared to USD 48.170 million a year ago. Net income was USD 35.681 million compared to USD 41.647 million a year ago. Basic earnings per share was USD 0.92 compared to USD 1.07 a year ago. Diluted earnings per share was USD 0.91 compared to USD 1.06 a year ago. For the half year, total revenue was USD 273.703 million compared to USD 265.480 million a year ago. Operating income was USD 110.716 million compared to USD 92.057 million a year ago. Net income was USD 89.066 million compared to USD 79.339 million a year ago. Basic earnings per share was USD 2.29 compared to USD 2.01 a year ago. Diluted earnings per share was USD 2.27 compared to USD 2.01 a year ago.

Latest news about China Biologic Products Holdings, Inc.

China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from S&P Global BMI Index	21-04-23	CI
China Biologic Products Holdings, Inc.(NasdaqGM:CBPO) dropped from FTSE All-World Index	21-04-23	CI
China Biologic Products Holdings, Inc.(NasdaqGS:CBPO) dropped from NASDAQ Biotechnology Index	21-04-20	CI
China Biologic Products Holdings, Inc.(NasdaqGM:) dropped from NASDAQ Composite Index	21-04-20	CI
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow, Chairman and Chief Executive Officer of China Biologic Products Holdings, Inc. completed the acquisition of remaining 31.16% stake in China Biologic Products Holdings, Inc..	21-04-19	CI
China Biologic Products Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-29	CI
China Biologic Products : Q4 Profit, Revenue Rise from Year Ago	21-03-29	MT
China Biologic Products Holdings, Inc. Announces Resignation of Yue’e Zhang from the Board of Directors	21-01-07	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 9.72% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	21-01-05	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO completed the acquisition of 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	21-01-04	CI
CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited.	20-12-29	CI
Transcript : China Biologic Products Holdings, Inc., Q3 2020 Earnings Call, Nov 25, 2020	20-11-25
China Biologic Products Holdings, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-24	CI
China Biologic Products : Q3 Adj. EPS Slips From Year-Ago Levels But Sales Climb Nearly 2%	20-11-24	MT
China Biologic Products : to Merge With CBPO Group in Going-Private Deal; Shares Gain Pre-Bell	20-11-19	MT
Centurium Capital Management Ltd., CITIC Capital Partners Management Ltd., Parfield International Ltd., V-Sciences Investments Pte Ltd, Hillhouse Capital Management, Ltd. and Joseph Chow entered into a definitive Agreement and Plan of Merger to acquire remaining 31.16% stake in China Biologic Products Holdings, Inc. for $1.6 billion.	20-11-18	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 9.72% stake in China Biologic Products Holdings, Inc. for approximately $450 million.	20-10-26	CI
Joseph Chow, the Chairman of the Board of Directors and Chief Executive Officer of CBPO entered into a share purchase agreement to acquire 2% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for $93 million.	20-10-26	CI
CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. from PW Medtech Group Limited for approximately $110 million.	20-10-26	CI
Transcript : China Biologic Products Holdings, Inc., Q2 2020 Earnings Call, Aug 18, 2020	20-08-18
China Biologic Products Holdings, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-17	CI
Transcript : China Biologic Products Holdings, Inc., Q1 2020 Earnings Call, May 21, 2020	20-05-21
China Biologic Products Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-20	CI
China Biologic Comments on the Xinjiang Deyuan and Shuanglin Transaction	20-05-20	CI
Hillhouse Capital Provides Information to Shareholders of China Biologic	20-05-08	CI

Chart China Biologic Products Holdings, Inc.

Duration

Period

Chart China Biologic Products Holdings, Inc.

More charts

Company Profile

China Biologic Products Holdings Inc is a China-based company. The Company operates as a biopharmaceutical company. The Company research, develop, and produces human plasma-based pharmaceutical and coagulation factor products in the form of tablets, injections, capsules, and syrups. Company also distributes pharmaceutical products. It serves clients in China.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
ARGENX SE	+0.76%	22.27B
BIONTECH SE	-12.64%	22.22B
GENMAB A/S	-4.50%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
NEUROCRINE BIOSCIENCES, INC.	+7.77%	14.29B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B

Bio Therapeutic Drugs